Ibogaine is currently not scheduled under the Dutch Opium Act (Opiumwet), meaning it occupies an unscheduled legal status in the Netherlands — though this status has attracted regulatory attention and should be independently verified. Last verified: April 2026.

Not Legal Advice. This page is for informational purposes only. Dutch drug law is subject to regulatory reinterpretation, and ibogaine's status may shift without prominent public notice. Consult a licensed Dutch attorney or a pharmacist registered with the Inspectie Gezondheidszorg en Jeugd (IGJ) before making any decisions.

Current Legal Status

The Netherlands regulates controlled substances primarily through the Opiumwet (Opium Act), which divides substances into two lists: List I (hard drugs, e.g., heroin, cocaine, MDMA) and List II (soft drugs, e.g., cannabis). Ibogaine — and its primary active alkaloid ibogaine hydrochloride — does not appear on either list as of April 2026.

Because ibogaine is not scheduled, it is not subject to the criminal prohibitions that apply to List I or List II substances. It is also not currently classified as a medicine (geneesmiddel) by the Dutch Medicines Evaluation Board (College ter Beoordeling van Geneesmiddelen, CBG-MEB), which means it cannot be legally prescribed or dispensed through pharmacies as a registered pharmaceutical product.

This creates a legally ambiguous situation: ibogaine is neither explicitly legal nor explicitly prohibited, but its administration in a clinical or ceremonial context may trigger scrutiny under:

  • The Medicines Act (Geneesmiddelenwet) — if ibogaine is presented, marketed, or administered as a treatment for a medical condition, authorities could argue it functions as an unregistered medicine.
  • The Individual Health Care Professions Act (BIG-wet) — which governs what medical procedures licensed health professionals may perform.
  • General duty-of-care obligations — operators of any health or wellness service carry legal liability if a participant is harmed.

There are no formal religious or sacramental exemptions to ibogaine's use in the Netherlands, unlike the peyote/mescaline exemptions seen in some jurisdictions.

Treatment Centers

The Netherlands has historically been home to several ibogaine treatment providers, reflecting its generally progressive approach to drug policy and harm reduction. Because ibogaine is unscheduled, clinics and retreat operators have been able to function without facing direct prosecution under the Opium Act — though they remain subject to the regulatory considerations described above.

Dutch-based providers tend to emphasize medical screening, cardiac monitoring (ibogaine carries well-documented QT-prolongation risk), and pre- and post-integration support. Quality and standards vary significantly between operators.

For a current, vetted directory of treatment centers operating in the Netherlands, visit our full clinic directory.

How People Access Ibogaine in the Netherlands

Given ibogaine's unscheduled status, people currently access it in the Netherlands through several routes. This section is purely factual and does not constitute a recommendation for any particular pathway.

  • Private retreat centers and clinics: A number of operators — ranging from medically supervised clinics with on-site physicians to more ceremony-focused retreat providers — offer ibogaine sessions. These facilities typically require pre-screening questionnaires, electrocardiograms (ECGs), and blood work before admission.
  • Underground or informal settings: As in many countries, some people access ibogaine through informal networks. This carries substantially higher risk due to the absence of medical oversight.
  • Importation for personal use: Some individuals import ibogaine or iboga root bark (from Tabernanthe iboga) from other countries. Import is not explicitly prohibited under the Opium Act, but customs authorities may apply scrutiny depending on quantities and declared purpose. The iboga plant itself is not listed on CITES appendices in a way that would automatically prohibit import, but national customs rules apply.
  • Research contexts: Academic institutions and researchers in the Netherlands have conducted or participated in ibogaine-related studies. Access in this context is governed by institutional ethics boards and, where applicable, clinical trial regulations.

Recent Legal Developments

While ibogaine has remained unscheduled in the Netherlands, several developments over recent years are worth noting:

  • Growing regulatory scrutiny of psychedelic providers: Dutch authorities have increased oversight of operators in the broader psychedelic therapy space — most visibly with psilocybin truffles, which are legal, and with ayahuasca ceremonies, which have faced intermittent police action. This heightened attention creates a general regulatory climate in which ibogaine providers should not assume their unscheduled status guarantees immunity from scrutiny.
  • Medicines Act enforcement actions: The Inspectie Gezondheidszorg en Jeugd (IGJ), the Dutch health and youth inspectorate, has shown increased willingness to act against unregistered medicine claims. Ibogaine providers who market sessions using language implying medical treatment of addiction or other conditions risk IGJ attention.
  • International pressure and EU harmonization: As European Union member states discuss drug policy harmonization and as the WHO continues to evaluate psychoactive substances, there is a possibility that ibogaine could be subject to future scheduling reviews. No concrete EU-level proposal to schedule ibogaine is publicly known as of April 2026, but the regulatory environment is not static.
  • Cardiac safety discourse: High-profile reporting on ibogaine-related cardiac deaths — including a landmark study published in 2023 examining ibogaine's effects on veterans with traumatic brain injury, which highlighted both efficacy signals and cardiac risks — has intensified medical community and public health discussions in the Netherlands and abroad.

Risks of Seeking Treatment in the Netherlands

The absence of scheduling does not mean ibogaine is without risk. People considering treatment in the Netherlands should be aware of the following:

  • No standardized regulatory framework for ibogaine providers: Unlike a regulated pharmacy or hospital, ibogaine clinics and retreat centers in the Netherlands operate without a specific licensing regime for ibogaine administration. There is no government-mandated certification for ibogaine facilitators.
  • Cardiac risk is serious: Ibogaine prolongs the QT interval and has been associated with cardiac arrhythmias and death, particularly in individuals with undetected heart conditions, those taking contraindicated medications, or those with electrolyte imbalances. Reputable Dutch providers require ECGs; informal settings may not.
  • Variable quality of screening: The depth of medical pre-screening varies widely between operators. There is no national minimum standard.
  • Drug interaction risks: Ibogaine has serious interactions with opioids, SSRIs, stimulants, and many other substances. Anyone seeking treatment for opioid use disorder must manage opioid cessation carefully before administration.
  • Legal liability ambiguity: If something goes wrong, the legal recourse available to a patient injured during an ibogaine session in an informal or unregistered setting may be limited and complex.
  • Provider due diligence: Prospective patients should verify physician credentials, ask to see the clinic's emergency response protocols, confirm access to resuscitation equipment and a defibrillator, and request references or verifiable outcome data.

Frequently Asked Questions

Ibogaine is not listed on either schedule of the Dutch Opium Act (Opiumwet), so it is technically unscheduled — meaning it is not a controlled substance under that law. However, "unscheduled" is not the same as "explicitly legal in all contexts." Administering ibogaine as if it were a medicine, or doing so without adequate medical safeguards, could attract attention under the Medicines Act or health inspectorate regulations. This status should be independently verified with a Dutch legal professional, as regulatory discussions have occurred.
Because ibogaine is not scheduled under the Opium Act, there is no automatic prohibition on importing it analogous to a controlled drug. However, customs authorities have broad discretion, and importing any substance with psychoactive properties in significant quantities can draw scrutiny. The legal status of ibogaine in the country of origin also matters. Anyone considering importation should obtain specific legal advice before doing so.
Ibogaine providers in the Netherlands operate in a legal grey zone. Because ibogaine is unscheduled, they are not violating the Opium Act by possessing or administering it. However, if a clinic makes medical claims about treating addiction or other conditions, it risks classification as an unregistered medicine provider under the Geneesmiddelenwet. Reputable Dutch providers typically work with legal counsel to frame their services carefully and comply with applicable health and safety obligations.
No. Because ibogaine is not a registered medicine and ibogaine therapy is not an approved treatment under Dutch health policy, Dutch health insurers (zorgverzekeraars) do not cover it. Costs are paid out of pocket. Prices at Dutch clinics vary widely depending on the length of the program, level of medical oversight, and accommodation provided.
It is possible. The Dutch government can amend the Opium Act schedules through a ministerial decree following advice from the Coördinatiepunt Assessment en Monitoring nieuwe drugs (CAM), the body that evaluates new psychoactive substances. If ibogaine were assessed as posing significant public health risks, it could be proposed for scheduling. No formal scheduling proposal was publicly active as of April 2026, but the regulatory environment is subject to change, particularly given EU-level discussions on psychoactive substances.
At minimum, look for providers who require a pre-treatment ECG and full blood panel, have a licensed physician present during or immediately available throughout the session, maintain a defibrillator and emergency response plan on-site, conduct thorough medication and substance use history screening, and offer structured integration support before and after the session. Facilities that skip or minimize these steps represent a substantially higher risk. Do not accept reassurances that ibogaine is "safe" without evidence of these safeguards.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.